Cerebras Shares Are Coming Out of Lockup in Waves. Here's the Date That Matters Most.

Cerebras Systems has already released nearly 113 million of an estimated 171 million early-unlock shares, with three additional tranches of roughly 19.4 million shares each scheduled for Sept. 30, Oct. 14, and Oct. 28. The remaining locked shares are likely to become eligible for sale on Nov. 9, potentially creating another supply overhang for CBRS, which trades near $199 versus a day-one peak above $386 and an IPO price of $185. The supply risk is offset by strong operating momentum: Q2 revenue rose 74% year over year to about $180 million and remaining performance obligations were $25.4 billion, though materially concentrated with OpenAI.

Analysis

CBRS now trades as a flow-driven AI proxy rather than a clean fundamental rerating: each incremental float expansion lowers the scarcity premium, widens the potential shareholder base, and gives early holders an opportunity to diversify concentrated paper gains. The relevant signal is not the scheduled eligibility date itself, but whether block trades print below VWAP and whether daily volume absorbs the newly tradable shares without persistent price concessions. A quiet release date should therefore be read as evidence of limited immediate selling intent, not as proof that the overhang has cleared.

The highest-risk window is the Q3 reporting/terminal-unlock overlap in the next 1-2 months. Any revenue, margin, delivery-timing, or backlog-conversion disappointment would arrive when natural incremental supply is greatest, amplifying downside through reduced liquidity support and multiple compression. Customer concentration also means that changes in one large buyer's deployment cadence can matter more to valuation than aggregate AI demand; a large contracted backlog should not be valued equivalently to diversified, near-term revenue until conversion and payment terms are demonstrated.

Consensus may overstate the mechanical bearishness of the final expiry: sophisticated holders can hedge or distribute ahead of the date, and restrictions on insider sales may stagger realized selling. The more constructive contrarian setup emerges only if CBRS holds above its IPO reference area through the final unlock while volume materially exceeds normal turnover—evidence that new institutional demand is replacing legacy holders. Structural upside over 6-18 months remains contingent on proving that its architecture converts backlog into durable gross margin and reduces dependence on a small customer set, not on the lockup calendar ending.

Key Decisions for Investors

• Do not add directional CBRS exposure ahead of the Sept. 30-Oct. 28 release sequence; monitor block-trade discounts, closing-price/VWAP behavior, and borrow utilization as the actionable flow indicators.
• For a tactical bearish expression, prefer a defined-risk CBRS put spread spanning the expected Q3-results/final-unlock window, but only if listed-option liquidity and implied volatility permit a reasonable premium. Target a 4-8 week holding period; abandon if the stock closes above $246 on strong volume and management raises near-term delivery or margin guidance.
• If borrow is available at an acceptable rate, consider a small pair: short CBRS / long NVDA, sized beta-neutral, initiated only on a failed rally into $210-$220. The pair isolates float-expansion, execution, and customer-concentration risk while retaining AI-compute exposure; cover on a sustained hold above $246 or evidence that institutional demand absorbs unlock-related selling.
• Set a post-Nov. 9 alert rather than pre-committing to a long: initiate a starter long only if CBRS sustains above the IPO reference level for 5-10 trading days after final eligibility, daily volume normalizes, and Q3 results show backlog conversion without a material deterioration in gross margin or customer concentration.